Eli Lilly lifts for Jaypirca and Medicare access, shares at record high

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-27, 12:46.

Eli Lilly & Co. (US5324571083) pairs a regulatory advance for Jaypirca with Medicare access details for its GLP-1 portfolio. Reuters-linked market coverage and the latest U.S. close frame the move on the NYSE.

Jaypirca gets the market's attention

Investing.com reported that Eli Lilly shares surged 5.7 percent in morning trading after the European Medicines Agency's CHMP issued a positive opinion for Jaypirca in chronic lymphocytic leukemia across all lines of therapy. The same report said the application now moves to the European Commission for a final decision expected within one to two months. Investing.com report on the Jaypirca update

The same market note linked the session to Lilly's Medicare GLP-1 Bridge Program, scheduled to launch on July 1, 2026. It said eligible Medicare Part D patients can access Zepbound and Foundayo for 50 USD per month, with an estimated 20 million patients meeting the clinical criteria.

Wall Street stays constructive

Leerink Partners raised its price target on LLY to 1,232 USD from 1,119 USD and kept an Outperform rating, according to the market report cited by Investing.com. That revision came alongside the session's broad rally and gives the stock another dated analyst anchor. Analyst update in the same market report

The latest close on TradingKey showed Eli Lilly shares at 1,208.12 USD on June 26 at 16:00 ET, up 7.01 percent from the prior close. TradingKey also listed a market capitalization of 1.14 trillion USD and a trailing P/E of 42.84. TradingKey quote page for LLY

How Lilly makes money

Jaypirca is an oral oncology medicine, while Zepbound and Mounjaro sit at the center of the company's obesity and diabetes franchise. Those products are the main commercial backdrop behind the recent analyst and market reaction.

NYSE close in focus

The Eli Lilly shares (US5324571083) trade on June 26, 2026, at 16:00 ET on the NYSE at 1,208.12 USD.

Disclaimer: Market data can change quickly. This article is for information only and does not constitute investment advice.